Meeting
2021 ASCO Annual Meeting
Risk factors associated with skeletal-related events following denosumab cessation among patients with bone metastases from solid tumors: A real-world machine learning approach.
Authors
Alison Stopeck
Stony Brook Cancer Center, Stony Brook University, Stony Brook, NY
Alison Stopeck , Celestia S. Higano , David H. Henry , Basia A. Bachmann , Marko Rehn , Dionna Jacobson , Benoit Cadieux
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Care Delivery and Regulatory Policy
Track
Care Delivery and Quality Care
Sub Track
Digital Technology
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 1567)
DOI
10.1200/JCO.2021.39.15_suppl.1567
Abstract #
1567
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Efficacy and safety of denosumab from a phase III, randomized, active-controlled study compared with zoledronic acid in patients of Asian ancestry with bone metastases from solid tumors.
First Author: Zefei Jiang
Poster
2021 ASCO Quality Care Symposium
Treatment initiation with bone-targeting agents among patients with bone metastasis secondary to solid tumors or patients with multiple myeloma.
First Author: Oth Tran
Poster
2021 ASCO Annual Meeting
Bone modifying agents in veterans with castration-resistant prostate cancer.
First Author: Jordan Bauman
Poster
2021 Genitourinary Cancers Symposium
Use of bone modifying agents in patients with metastatic castrate-sensitive prostate cancer.
First Author: Aaron Philip Mitchell